1. DOP51 Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients. (30th January 2023) Authors: Hageman, I; Joustra, V; Zafeiropoulou, K; Davids, M; Hakvoort, T; Probert, F; Satsangi, J; D'Haens, G; De Jonge, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗